In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EAPC Ivory (& above) Members, Fellows of the ESC and Young combined Members

The prevalence of smoking and association with arterial hypertension in pupils

Session Poster Session III - Saturday 08:30 - 12:30

Speaker Vadim Kuznetsov

Congress : EuroPrevent 2017

  • Topic : preventive cardiology
  • Sub-topic : Tobacco
  • Session type : Poster Session
  • FP Number : 769

Authors : VA Kuznetsov (Tyumen,RU), EI Gakova (Tyumen,RU), ЕV Akimova (Tyumen,RU), MM Kayumova (Tyumen,RU), AA Gakova (Tyumen,RU)

VA Kuznetsov1 , EI Gakova1 , ?V Akimova1 , MM Kayumova1 , AA Gakova1 , 1Tyumen Cardiology Research Center, Tomsk National Research Medical Center - Tyumen - Russian Federation ,

European Journal of Preventive Cardiology ( April 2017 ) 24 ( Supplement 1 ), 170

Background: Smoking is one of the major risk factors for cardiovascular diseases.
Purpose: To assess the epidemiology of arterial hypertension (AH) and the risk factors associated with it among Tyumen pupils’ population for designing of main preventive measures.
Methods: The cross-sectional epidemiology study of pupils’ population in one of administrative districts in Tumen selected as per the random was performed. 2640 pupils (1308 boys and 1332 girls) aged 7-17 with response 87.7 % were studied during the cardiology screening. Attitude to smoking was estimated by anonymous questionnaire according to the standard form: smokers were considered pupils who smoked at least one cigarette per week. AH was assessed according to the WHO guidelines using criteria of high systolic and diastolic BP for children: at age 7-9 years >120/70 mmHg; at age 10-12 years >120/75 mmHg; at age 13-14 years >130/ 80 mmHg; at age 15-17 years ≥135/ 85 mmHg. Statistical analysis of the results was carried out using «Statistika 6.0» programme including correlation analysis, univariate regression analysis (calculating Student’s t-test, F-Fisher’s exact test, Х2-Pearson’s chi-square test, Cramér's V test) where statistically significant differences were as р<0.05.
Results: The study showed the growth of active smokers among pupils of every following age group: at boys aged 7-17 years increased from 1.2% to 23.7% vs girls aged 13–17 years – from 3.3% to 10.0%. More than 52 % of pupils are passive smokers. Higher prevalence of increased BP among smoking pupils as compared to non-smoking (13.5% vs 11.6%; for boys 14.3% and 13.6% vs 11.9% and 9.6% for girls) was detected. Univariate regression analysis established the contingency between elevated diastolic BP and active smoking as follows: calculated Х2-Pearson criterion =115.2261, df=36, achieved significance value for degrees-of-freedom p<0.001; Spearman's degree of dependence R=0.22, t=2.27 (p=0.025). The intensity of the relationship between diastolic BP and smoking according to Cramér's V was detected as 0.767. Moreover, weak feedback between elevated systolic BP and passive smoking was found.
Conclusion: Thus, the cross-sectional epidemiology study of Tyumen pupils’ population showed the association between AH level and active and passive smoking. This fact requires design and implementation of targeted and effective preventive measures.

The free consultation period for this content is over.

It is now only available year-round to EAPC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are